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Abstract
Background: To retrospectively access outcome and prognostic parameters of linear accelerator-based stereotactic
radiosurgery in brain metastases from malignant melanoma.
Methods: Between 1990 and 2011 140 brain metastases in 84 patients with malignant melanoma (median age
56 years) were treated with stereotactic radiosurgery. At initial stereotactic radiosurgery 48 % of patients showed
extracerebral control. The median count of brain metastases in a single patient was 1, the median diameter was
12 mm. The median dose applied was 20 Gy/80 % isodose enclosing.
Results: The median follow-up was 7 months and the median overall survival 9 months. The 6-, 12- and 24 month
overall survival rates were 71 %, 39 % and 25 % respectively. Cerebral follow-up imaging showed complete remission in
20 brain metastases, partial remission in 39 brain metastases, stable disease in 54 brain metastases, progressive disease
in 24 brain metastases and pseudo-progression in 3 brain metastases. Median intracerebral control was 5.3 months and
the 6- and 12-month intracerebral progression-free survival rates 48 % and 38 %, respectively. Upon univariate analysis,
extracerebral control (log-rank, p < 0.001), the response to stereotactic radiosurgery (log-rank, p < 0.001), the number of
brain metastases (log-rank, p = 0.007), the recursive partitioning analysis class (log-rank, p = 0.027) and the diagnosis-
specific graded prognostic assessment score (log-rank, p = 0.011) were prognostic for overall survival. The most
common clinical side effect was headache common toxicity criteria grade I. The most common radiological finding
during follow-up was localized edema within the stereotactic radiosurgery high dose region.
Conclusion: Stereotactic radiosurgery is a well-tolerated and effective treatment option for brain metastases in
malignant melanoma and was able to achieve local remissions in several cases. Furthermore, especially patients with
controlled extracerebral disease and a low count of brain metastases seem to benefit from this treatment modality.
Prospective trials analysing the effects of combined stereotactic radiosurgery and new systemic agents are warranted.
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Background
The predicted 2012 standardized disease rate for malig-
nant melanoma (MM) in Germany for women is 15.6
and for men 16.9 per 100.000 persons, respectively [1].
Even though incidence rates worldwide have increased
over the past decades, recent developments indicate
stabilization in some high-risk countries [2]. Risk factors
for the development of brain metastases (BM) are for ex-
ample positive sentinel lymph nodes and primary tumor
ulceration [3, 4]. Unfortunately, the prognosis with BM
from MM is poor and varies between a median overall
survival of 3.5 months after whole brain radiotherapy
(WBRT) in case of multiple BM [5] and an actuarial me-
dian survival of 10.6 months after stereotactic radiosur-
gery (SRS) of single BM [6]. Another well-established
approach is the resection of BM [7, 8] while upcoming
systemic therapies have not shown to be adequately effect-
ive in BM from MM [9]. Prognostic factors include the
Radiation Therapy Oncology Group recursive partitioning
analysis (RTOG-RPA) class [10], diagnosis-specific Graded
Prognostic Assessment (ds-GPA) score [11] and serum-
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lactate dehydrogenase (LDH) values [12]. This retrospect-
ive analysis was focused on patients with BM from MM
treated with SRS to evaluate outcome and SRS-related
side effects.
Methods
Patient characteristics Between 1990 and 2011 181 pa-
tients with BM from MM were treated with linear acceler-
ator (Linac)-based SRS at the Department of Radiation
Oncology at the University Hospital of Heidelberg. Eighty-
four patients with available imaging follow-up were in-
cluded in this analysis; the remaining 97 patients without
imaging follow-up were excluded from analysis. At initial
SRS 48 % of patients showed extracerebral control. The
median count of BM in a single patient was 1 and the me-
dian diameter 12 mm. Thirty-eight patients had > 1 BM
treated with SRS. LDH levels were not evaluated on a
regular basis. Further patient characteristics are found in
Table 1.
Radiotherapy and follow-up
SRS applied a median dose of 20 Gy on the enclosing 80 %
isodose. SRS was performed Linac-based using 6-mega
electron volt (MeV) photon beams with either a round
collimator or individually shaped by a micro-multileaf col-
limator. Head fixation was ensured by Scotchcast-masks.
Patients were regularly followed by clinical examinations
and imaging procedures as computer tomography (CT) or
magnetic resonance imaging (MRI). Salvage treatments
consisted of whole brain radiotherapy, surgical resection
of the BM, and chemo- or more recently immunotherapy.
Evaluation and statistics
The toxicity was graded according to the Common Tox-
icity Criteria for Adverse Events (CTCAE Version 4).
The Kaplan-Meier survival analysis was used to estimate
survival curves. Univariate analysis included age (>/<
median age), gender, localization of the BM (infra- vs.
supratentorial), number of BM (total and grouped 1 vs. 2–
3 vs. >3), response to SRS (remission (including complete
and partial remission) vs. stable disease vs. progressive dis-
ease), size of BM (>/< median), extracerebral tumor con-
trol (yes vs. no), Karnofsky performance score (90–100 vs.
70–80 vs. <70), RPA (1 vs. 2 vs. 3), ds-GPA (2 vs. 3 vs. 4),
WBRT during follow-up (yes vs. no) and clinical symp-
toms prior to SRS (yes vs. no). Multivariate analysis was
performed with the Cox-regression model (backwards
stepwise, p out >0.1). Multivariate analysis included the
significant factors from univariate analysis: extracerebral
control, ds-GPA score, RPA class, number of BM and re-
sponse to SRS. Significance was defined as p < 0.05. Cor-
relation of the treatment response after SRS in patients
with 2 or more BM treated with SRS was analyzed using
Spearman correlation coefficient. All time estimates began
Table 1 Patient characteristics
Patient characteristics % [n]
Gender
Male 55 46
Female 45 38
Age at initial SRS
Median 56 years (range, 19–94)
Clark level
II 2 2
III 5 4
IV 44 37
V 4 3
n. a. 45 38
Histopathology
ALM 5 4
AMM 5 4
NM 18 15
SSM 21 18
n. a. 52 43
Extracerebral tumor control
Uncontrolled 52 44
Controlled 48 40
RPA class
1 11 9
2 87 73
3 2 2
DS-GPA score
2 15 13
3 43 36
4 42 35
Symptomatic before SRS
No 67 56
Yes 33 28
Number of BM at initial SRS
1 58 49
2–3 37 31
≥4 5 4
Size of BM
Median 12 mm (range, 2–36 mm)
Localization of BM at initial SRS
Infratentorial 8 7
Supratentorial 85 71
Both 7 6
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with the date of SRS. The statistical analyses were carried
out using SPSS (SPSS Inc., Chicago, IL, USA). Informed
consent was obtained. The study was approved by the
Ethics Committee of the University of Heidelberg (S-004/
2012).
Results
Outcome The median OS was 9 months (95 % CI 8–10
months). The 6-, 12- and 24-months OS rates were 71 %,
39 % and 25 % (Fig. 1). At the last follow-up examination
in July 2014, 11 patients were still alive. Causes of death
were documented in 6 patients only: intracerebral pro-
gression in 4 patients and peritoneal carcinomatosis as
well as pulmonary embolism in 1 patient each. The median
follow-up time was 7 months (range, 0.2–199.2 months).
Cerebral follow-up imaging showed a complete remission
(CR) in 20 BM, a partial remission (PR) in 39 BM, stable
disease (SD) in 54 BM, progressive disease (PD) in 24 BM
and a histopathologically proven pseudo-progression in 3
BM. The median intracerebral control time was 5.3 months
resulting in 6- and 12-months intracerebral progression-
free survival rates of 48 % and 38 % (Fig. 2).
Prognostic factors The results of the uni- and multi-
variate analyses are presented in Table 2. In univariate
analyses, extracerebral tumor control (p < 0.001, uncon-
trolled 6.8 months vs. controlled 12.4 months), response
to SRS (p < 0.001, progressive disease 4.3 months vs.
stable disease 8.3 months vs. remission 13.3 months),
number of BM (linear p = 0.007; grouped p = 0.005, n > 3
8.3 months vs. n = 2–3 5 months vs. n = 1 12.4 months),
RPA class (p = 0.027, class 1 37.8 months vs. class 2
8.3 months versus class 3 3.3 months) and ds-GPA (p =
0.011, score 2 5 months vs. score 3 8.8 months vs. score 4
12.4 months, Fig. 3) were prognostic for overall survival
(OS). In multivariate analysis extracerebral tumor control
(p < 0.001), response to SRS (p < 0.001) and the grouped
number of BM (p = 0.006) were prognostic. In patients
with 2 or more BM treated with SRS the treatment re-
sponse after SRS correlated significantly (Spearman cor-
relation coefficient 0.684).
Side effects Acute side effects within the first three days
after SRS were seen in 6 % (n = 5): headache CTCAE °I
was reported by 3 patients, muscle weakness CTCAE °II
by 1 patient and temporary worsening of pre-existing
paresthesias CTCAE °I by one other patient. Acute side
effects within the first 3 months were documented in 13
patients (15 %; Table 3). Late (>3 months) side effects
were documented in 2 patients (Table 3).
Discussion
This retrospective single-center analysis reports on pos-
sible prognostic factors, outcome and toxicity of SRS in
140 BM from MM treated between 1990 and 2011 and
followed by cerebral imaging. Our intention was to help
find ways to improve prognosis, morbidity and mortality
in patients with BM from MM. Literature on treatment
outcome is summarized in Table 4.
Liew et al. reported in 2011 on 333 consecutive pa-
tients treated with Gamma Knife SRS for BM from MM
[13]. The median follow-up was 3.8 months and the
Fig. 1 Kaplan-Meier estimation of overall survival (n = 84)
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median survival 5.6 months. In the analysis published by
Bernard et al. encompassing 54 patients with BM from
MM, the median survival after SRS for intact BM (n = 34)
was 4 months, compared to 13 months after prior resec-
tion (n = 20) of the BM [14]. Recently, Marcus and co-
workers reported a median OS of 6.9 months in 135 pa-
tients treated with SRS for BM from MM [12]. In com-
parison our results showing a median OS of 9 months and
12- and 24 months OS rates of 39 % and 25 %, respect-
ively, are superior to these prior reports. This difference
might be explained by a selection bias for follow-up im-
aging in our analysis or different approaches in systemic
therapy in case of tumor progression.
With respect to local control Liew et al. reported a
median progression-free survival of 30 months with
progression-free survival rates of 63 % at 12 months and
57 % at 24 months after SRS [13]. Follow-up imaging in
259 patients with 1226 BM showed CR in 6 %, PR in
23 %, SD in 61 % and PD in 10 %. In the cohort of Lwu
et al. on 36 patients treated with Gamma Knife SRS (me-
dian prescription dose 21 Gy) for BM, 20 patients suffered
from melanoma [15]. The local control at 12 months was
75 % for melanoma patients. In our cohort comparable
response rates were observed. The diagnosis of pseudo-
progression in all of our 3 cases was based on histopatho-
logical examination following surgical resection of the
lesion.
Regarding the number of BM, Liew et al. reported pa-
tients suffering from single BM to have median survival
of 8.2 months, compared to 4.1 months with multiple
BM [13]. This prognostic difference is in accordance
with our results, which showed significantly shorter sur-
vival times with increasing number of BM. On the other
hand, in the smaller patient group of Marcus et al., the
number of BM had no significant impact on survival
[12]. In the cohort of Bernard et al., an increasing
Fig. 2 Kaplan-Meier estimation of intracerebral progression-free survival
Table 2 Uni- and multivariate analyses
Univariate analysis (log-rank) p-value
Gender (male vs. female) 0.587
Age (>/< median) 0.498
Extracerebral tumor control (yes vs. no) <0.001
KPS (grouped 90–100 vs. 70–80 vs. <70) 0.649
RPA (1 vs. 2 vs. 3) 0.027
ds-GPA (2 vs. 3 vs. 4) 0.011
WBRT (yes vs. no) 0.082
Symptoms prior to SRS (yes vs. no) 0,228
Number of BM (grouped 1 vs. 2–3 vs. >3) 0.005
Number of BM (total) 0.007
Location (infra- vs. supratentorial) 0.792
Response to SRS (remission vs. stable vs. progression) <0.001
Size of BM (>/< median) 0.125
Multivariate Analysis (Cox-regression model) p-value
Extracerebral tumor control (yes vs. no) <0.001
ds-GPA (2 vs. 3 vs. 4) 0.078
RPA (1 vs. 2 vs. 3) 0.208
Number of BM (grouped 1 vs. 2–3 vs. >3) 0.006
Response to SRS <0.001
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number of BM showed a trend towards shorter survival
[14]. This difference might be due to selection bias
caused by different treatment approaches in the different
clinics.
The adverse events documented in our cohort were
comparable to previous reports. One case of focal alope-
cia was due to superficial location of the BM and not
unexpected when reviewing the treatment plan and dose
distribution. One case with imaging diagnosis of central
nervous system necrosis grade I was followed without
intervention. Silk et al. reported on patients treated with
ipilimumab and radiation therapy for BM from MM. In
their comparison group intratumoral haemorrhage hap-
pened in 12.5 % of cases, radiation necrosis in 3 cases
[16]. In an analysis by Kondziolka the haemorrhage rate
was up to 50 % in BM from MM [17]. The diagnosis of
pseudo-progression of cerebral lesions following radiation
treatment is challenging. Hoefnagels et al. as well as
Mitsuya et al. recommended perfusion MRI (PWI) to dif-
ferentiate between progression and pseudo-progression
[18, 19]. Recently Wiggenraad et al. analysed 10 patients
with pseudo-progression following SRS of BM and con-
cluded that consecutive MRIs using cine-loops may
improve understanding of pseudo-progression [20]. How-
ever, in their analysis on PWI, magnetic resonance spec-
troscopy and amino-acid positron emission tomography
Kickingereder et al. concluded that technical limitations
were problematic, comparative studies warranted and
Fig. 3 Kaplan-Meier estimation of overall survival according to the ds-GPA score (score 2, n = 13; score 3, n = 36; score 4, n = 35)
Table 3 Acute and chronic adverse events according to CTCAE
Acute adverse events % [n]
Localized edema
°I 5 [6]
°II 2 [2]
°III 1 [1]
Headache
°I 3 [4]
Alopecia
°I 1 [1]
Dizziness
°I 1 [1]
Nausea
°I 1 [1]
Intracranial hemorrhage
°I 1 [1]
Central nervous system necrosis
°I 1 [1]
Late adverse events
Localized edema
°I 1 [1]
°II 1 [1]
Central nervous system necrosis
°I 1 [1]
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stereotactic biopsies on structural MRI highly reliable to
differentiate between tumor progression and radiation-
induced changes [21].
However, patients with cerebrally metastasized MM
have a poor prognosis. Potential for improvement might
be found in the availability of new systemic therapies
and the combination of those with SRS. In recent years
systemic treatment options such as for example the de-
velopment of cytotoxic T-lymphocyte-associated Protein
4 antibodies or BRAF inhibitors improved outcome in
metastasized MM. Combined with SRS these systemic
agents might provide yet further improvement, but they
may also be a reason for major concern due to potential
harmful interactions. A retrospective analysis by Tazi et
al. suggested that survival of patients with BM from MM
treated with ipilimumab combined with SRS might be
comparable to those without BM [17]. Furthermore, an
abscopal effect of SRS after ipilimumab has been re-
ported prolonging the median survival to 22.4 months
[22]. Silk et al. reported a five time increase in the me-
dian survival after combination of ipilimumab and SRS
suggesting synergistic effects for this treatment ap-
proach [16]. Recently a study on 30 patients treated
with BRAF inhibitor and Gamma knife-SRS did not
show increased toxicity rates [23]. On the other hand
increased skin reactions have been reported for the
combination of BRAF inhibitors and radiotherapy de-
manding caution in combining new systemic agents and
radiation treatments [24, 25].
Regarding limitations of our study, the reader should
acknowledge its retrospective character and the changes
in systemic treatments during its 21 year recruiting time.
Prognostic markers like LDH levels or ulceration of the
primary tumor were not accessible due to the retrospective
character. In general, regular radiotherapeutic follow-up
examinations in patients with metastasized MM could be
challenging for example due to a decline in performance
status caused by progressive disease, long distance to the
radiation clinic or organizational difficulties in case of fur-
ther treatments elsewhere. Even though all available data
were carefully reviewed, a bias, for example in patient se-
lection for MR imaging during follow-up could not be
excluded. In recent years MRI capacities have increased
and therefore more precise imaging information during
follow-up is available than in earlier years. Furthermore,
causes of death were documented in a minority of patients
only. On the other hand our study has a reasonable num-
ber of treated BM and increases the available evidence for
treating BM from MM with SRS. Further evaluations of
prognostic markers and the immunological effects of sys-
temic agents as ipilimumab in combination with SRS or
whole brain radiation are warranted. Therefore we pre-
pared a prospective observational trial that started recruit-
ment recently.
Conclusion
SRS is a well-tolerated and effective treatment option in
brain metastases from malignant melanoma. Further-
more, remissions of BM could be achieved in some
cases. Especially patients with controlled extracerebral
disease and low count of BM seem to benefit from this
treatment modality. Prospective trials analysing the ef-
fects of a treatment approach combining new systemic
agents and SRS are warranted. A prospective observational
Table 4 SRS for BM from MM: overview of recent literature
Lwu 2013 Marcus 2013 Bernard 2012 Liew 2011 Present study
Number of patients 36 (20 melanoma) 135 54 333 84
SRS technique Gamma Knife SRS Cyber Knife Gamma Knife Linac based SRS
Median dose 21 Gy n. r. 24 Gy/80 % isodose 18 Gy marginal dose 20 Gy/80 % isodose
Follow-up [months] 6 n. r. 5 3.8 7
Count of BM [n] 1: 15 1: 80 Median 1 (1–6) 1: 122 1: 49
2–3: 35 2–3: 104 2–3: 31
≥2: 21 ≥4: 20 ≥4: 107 ≥4: 4
Response to SRS [%]
Remission 29 42
Stable n. r. n. r. n. r. 61 39
Progression 10 17
Median survival after SRS n. r. 6.9 4 5.6 9
12 months survival [%] n. r. 33.8 % with serum LDH < 240 15.4 %
with serum LDH≥ 240
25 24.9 39
24 months survival [%] n.r. n.r. n.r. 9.5 25
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study to analyse the immunologic effects of ipilimumab as
well as SRS is underway.
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